luteal-phase support in IVF cycles. Complication associated with artificial fertilization, unspecified
Conditions
Interventions
Intervention 1: group A: received 10 mg dydrogesterone QID (40mg daily) began on the day of oocyte retrieval and was continued up to 12 weeks of pregnancy. Intervention 2: group B: received 400 mg vag
Treatment - Drugs
group A: received 10 mg dydrogesterone QID (40mg daily) began on the day of oocyte retrieval and was continued up to 12 weeks of pregnancy.
group B: received 400 mg vaginal Progesterone twice per day (800 mg daily) began on the day of oocyte retrieval and was continued up to 12 weeks of pregnancy.
Sponsors
Infertility and Reproductive Health Research Center (IRHRC), IVF center,Shahid Beheshti University o
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: inclusion criteria: male factor infertility; euthyroid; normoprolactinemic. . exclusion criteria: tubal factor infertility; idiopathic infertility; endometriosis-related infertility and ovulatory disturbances; baseline FSH >12 IU; adenomyosis; uterine myoma; chronic hepatorenal disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy. Timepoint: six weeks following intervention. Method of measurement: sonography and pregnancy test.;Abortion. Timepoint: six weeks following intervention. Method of measurement: sonography and pregnancy test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Luteal-phase duration. Timepoint: 2 weeks following intervention. Method of measurement: patient history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Saghar Salehpour
Infertility and Reproductive Health Research Center (IRHRC), IVF center,Shahid Beheshti University o
Outcome results
None listed